Placenta mesenchymal dysplasia (PMD) is a rare placental anomaly associated with various fetal and maternal complications. Whether close ultrasound surveillance can prevent intrauterine fetal demise (IUFD) in patients with PMD is still under investigation. Amniotic fluid embolism (AFE) is a rare, lethal, and unpredictable maternal complication that has never been described in association with PMD. Here, we report a case of PMD, in which the fetus eventually demised in utero despite weekly color Doppler monitoring, and the mother subsequently encountered AFE during delivery.
Case presentation
A 43-year-old woman who had received three frozen embryo transfer, was found to have a singleton pregnancy with an enlarged multi-cystic placenta at 8 weeks’ gestation. Fetal growth restriction (FGR) was noted since the 21stweek. The fetus eventually demised in-utero at 25 weeks despite weekly color Doppler surveillance. Cesarean section was performed under general anesthesia due to placenta previa totalis and antepartum hemorrhage. During surgery, the patient experienced a sudden blood pressure drop and desaturation followed by profound coagulopathy. AFE was suspected. After administration of inotropic agents and massive blood transfusion, the patient eventually survived AFE. PMD was confirmed after pathological examination of the placenta.
Conclusions
While FGR can be monitored by color Doppler, our case echoed previous reports that IUFD may be unpreventable even under intensive surveillance in PMD cases. Although AFE is usually considered unpredictable, PMD can result in cumulative risk factors contributing to AFE. Whether a specific link exists between the pathophysiology of PMD and AFE requires further investigation.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PMD
Placenta mesenchymal dysplasia
AFEA
mniotic fluid embolism
AFP
Alpha fetoprotein
BWS
Beckwith-Wiedemann Syndrome
CPR
Cerebroplacental perfusion ratio.
DV
Ductus venosus
FGR
Fetal growth restriction
HCG
Human chorionic gonadotropin
IUFD
Intrauterine fetal demise
MS-PCR
Methylation-specific polymerase chain reaction
SFlt-1/PlGF
soluble fms-like tyrosine kinase-1 to placental growth factor ratio
VEGF
Vascular endothelial growth factor
Background
Placental mesenchymal dysplasia (PMD) is a rare pathological finding that manifests as an enlarged placenta covered with grape-like vesicles, which needs to be differentiated from molar pregnancies. PMD usually presents with a normal fetus, but is associated with 52% preterm delivery, 33% fetal growth restriction (FGR), 17% preterm premature rupture of membranes [1], and 29% intrauterine fetal demise (IUFD) [2]. Although surveillance with color Doppler is reasonable in the management of FGR, whether intensive ultrasound monitoring can prevent IUFD is still under debate.
As for maternal implications, 12.8% of PMD cases are associated with hypertensive disorders including preeclampsia, HELLP syndrome and eclampsia [3], whereas amniotic fluid embolism (AFE) has never been described in association with PMD. AFE is characterized by the triad of sudden blood pressure drop with desaturation, profound coagulopathy, and correlation with the timing of delivery. Although AFE is regarded unpredictable and unpreventable, it is notable that PMD can result in cumulative risk factors contributing to AFE. Herein, we report a case of PMD, in which the fetus eventually demised in utero, and the mother subsequently experienced AFE. To our knowledge, this is the first reported case of PMD complicated by AFE.
Anzeige
Case presentation
A 43-year-old woman with no systemic disease, gravida 4, para 1, conceived after the transfer of three frozen embryos. By the 8th week of gestation, a single gestational sac along with a thickened placenta was recorded. At 14th week gestation, the placenta thickened to 3.48 cm and presented with multiple vesicles. The fetus was nevertheless grossly normal. The initial differential diagnosis included partial mole, complete mole with a co-twin, Beckwith-Wiedemann syndrome (BWS), and PMD. Afterwards, blood test revealed an extremely high maternal serum human chorionic gonadotropin (HCG) level of 192,817.9 mIU/mL (MoM: 6.51) and an elevated alpha-fetoprotein (AFP) level of 397.2 ng/mL (MoM: 9.57). Amniocentesis confirmed a normal karyotype of 46, XX. Methylation-specific polymerase chain reaction (MS-PCR) showed no abnormal methylation in the imprinting control region H19 and KvDMR of chromosome 11p15, indicating that the fetus was not a case of BWS. Therefore, PMD was highly suspected.
Ultrasound surveillance was performed on a weekly basis. During the following weeks, we observed progressive enlargement of the hydropic placenta, and tortuous chorionic vessels with turbulent blood flow (Fig. 1 A, B, C). The hydropic placenta occupied the entire lower segment of the uterine cavity, resulting in placenta previa totalis. A symmetric growth delay of 1 week was first documented in the 21st week, while the amniotic fluid amount remained ample. The fetal umbilical artery and middle cerebral artery blood flow remained unremarkable until 25 weeks and 4 days gestation, when the patient came to our emergency department due to decreased fetal movements. After admission, ultrasound revealed placenta previa totalis, oligohydramnios and symmetric growth lag of 2 weeks. Color Doppler showed an unprecedented cerebroplacental perfusion ratio (CPR) of < 1, whereas the ductus venosus (DV) a-wave was normal. An elevated blood pressure and spot urine protein-creatinine ratio of 7.912 confirmed the diagnosis of preeclampsia. The ratio of soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1/PlGF) was 124.6. Tococardiography showed a category 2 fetal heart rate tracing. Preparation for preterm delivery using magnesium sulfate and betamethasone was initiated. However, on the second day of admission, the fetus demised in utero.
×
After confirmation of fetal demise, the patient experienced uterine contractions along with antepartum hemorrhage. Emergent cesarean section was immediately performed under general anesthesia due to active vaginal bleeding of 228 g in an hour and insufficient fasting time. During the operation, within 3 min following placental expulsion, the patient experienced a sudden blood pressure drop (from 141/76 mmHg to 42/32 mmHg), bradycardia (heart rate dropped from 92 bpm to 59 bpm), followed by desaturation (SpO2 80–83%). Intraoperative transesophageal echocardiography revealed a dysfunctional right ventricle. Therefore, AFE was suspected. Inotropic agents, massive blood transfusion and coagulation factor VII were instantly administered. Meanwhile, her blood test revealed a low platelet count of 58,000/μL (reference range 150,000-400,000/μL), prolonged prothrombin time of 15.6 s (reference range 9.5–11.7 s), activated partial thromboplastin time (APTT) of 68.0 s (reference range 24.3–3.27 s), a low plasma fibrinogen level of 53.7 mg/dL (reference range 200–400 mg/dL), and an elevated fibrin degradation product (FDP) level of 369.3 μg/ml (reference range < 5 μg/ml). Rotational thromboelastometry was used for optimal correction of the coagulation profile. A Bakri intrauterine balloon was inserted, yet fresh blood oozing from the vagina persisted despite adequate uterine contractions. We discussed with the patient’s husband and the necessity to proceed with hysterectomy if the bleeding persisted. However, concerning the patient’s desire for fertility and her relatively acceptable vital signs following blood transfusion (BP: 100/62 mmHg, HR: 71 bpm), we decided to try trans-arterial embolization (TAE) firstly. The patient later underwent TAE, and her condition was finally stabilized. The estimated intraoperative blood loss was 890 ml, and postpartum blood loss was 1500 ml initially. The total blood products transfused included 14 units of pRBC, 18 units of fresh frozen plasma, 2 units of single donor platelets, and 50 units of cryoprecipitate. A tranexamic acid pump was administered with continuous infusion for 1 day. The patient was discharged on day 9 of hospitalization.
The demised fetus was grossly normal, yet the specific cause of death could not be assessed due to the patient’s refusal for autopsy. The placenta weighed 1400 g (MoM = 5.19), sized 31 × 21 × 8 cm3. Under gross inspection, the placenta appeared edematous and was composed of grape-like vesicles (Fig. 2 A). The fetal surface showed dilated chorionic vessels, up to 3 cm in diameter. Another 7 × 6 x 2cm3 chorioangioma was attached to the placenta via a feeding vessel (Fig. 2 B). Microscopically, the hydropic stem villi were abnormally enlarged, with central cistern formation. The terminal villi appeared normal, with no excessive proliferation (Fig. 3A, B). All the above findings were consistent with PMD. The specimen collected from the placenta was further examined by MS-PCR, with hypermethylation found on the H19 gene and hypomethylation on the KvDMR gene, suggesting that androgenetic/biparental mosaicism is the etiology of PMD in this case.
×
×
Anzeige
Discussion
PMD is a rare pathological finding of the placenta with an estimated incidence of 0.002–0.02% [4, 5]. It can be detected as early as 8–9 weeks’ gestation, and early differentiation from gestational trophoblastic disease is crucial. Under color Doppler, the aneurysmal dilated chorionic vessels may demonstrate the “stained glass sign” [6], whereas in molar pregnancy, these areas tend to be absent of flow. Approximately 70% of patients with PMD present with abnormally elevated AFP levels and 38% with elevated HCG levels [1]. In contrast, patients with molar pregnancies typically have elevated HCG and normal AFP levels. Invasive diagnostic procedures, including chorionic villus sampling and amniocentesis, can provide information on fetal karyotype, while MS-PCR can further detect epigenetic changes [7]. The etiology of PMD includes congenital malformations of the mesoderm, molecular disruption of the imprinting genes of chromosome 11p15.5 associated with BWS, fetal aneuploidy, and androgenetic/biparental mosaicism [1, 8]. Among the reported cases of PMD, androgenetic/biparental mosaicism is the most common etiology, which happened to be the same etiology as in our case, as confirmed by MS-PCR [9].
According to the current literature, the diagnosis of PMD is mainly based on histological findings. A key feature that distinguishes PMD from molar pregnancy is that trophoblastic proliferation is typically absent in PMD, whereas trophoblastic proliferation with myometrial invasion is commonly observed in molar pregnancies [1]. Our patient presented with dilated, edematous stem villi with central cisterns and thickened fibromuscular stem vessels, whereas the terminal villi were normal. Our findings are consistent with the characteristics of PMD.
PMD is associated with 52% preterm delivery, 33% FGR, and 17% preterm premature rupture of membrane [1]. Ishikawa et al. reported a 29% rate of IUFD at a median gestational age of 31 weeks [2]. The cause of fetal death is likely to be multifactorial. Pham et al. proposed that diffused vascular malformations may lead to different extents of shunting and obstructive thrombosis within the vessels, resulting in poor perfusion and chronic hypoxia of the fetus [10]. Rupture of the inappropriately dilated chorionic vessels or major thrombotic events occurring within the umbilical cord may also cause sudden IUFD [10]. In addition, an increased expression of the vascular endothelial growth factor-D (VEGF-D) gene on chromosome Xp22.31 may be a consequence of chronic fetal hypoxia [4, 10]. The VEGF overexpression may contribute to the hypervascularity and chorangiosis commonly seen in PMD placentas. This explains the formation of a large chorioangioma attached to the hydropic placenta, as observed in our case [10].
Whether intensive monitoring can prevent fetal death in patients with PMD is still under investigation. Given the high risk of FGR in PMD cases, it is reasonable to incorporate color Doppler imaging into the management of PMD. However, 56% of IUFD cases occur in the absence of FGR [10]. In our patient, a CPR ratio < 1 was first documented 1 day ahead of IUFD, and the aortic isthmus and DV a-wave remained normal throughout the course. Therefore, we speculated that in addition to chronic hypoxia, a thromboembolic event was more likely the cause of fetal demise in our case. These results reflected the unpredictability of IUFD in patients with PMD.
Regarding maternal implications, 12.8% of PMD cases are associated with maternal hypertensive disorders, including preeclampsia, HELLP syndrome, and eclampsia [3]. Our patient presented with unprecedented episodes of hypertension and proteinuria along with an elevated sFlt-1/PlGF ratio of 124.6 at 25 weeks’ gestation. The imbalanced maternal serum anti-angiogenic markers could be a consequence of the chronic hypoxic fetus and placenta, eventually leading to preeclampsia [11, 12]. Given that early onset preeclampsia is typically associated with placental insufficiency and trophoblastic invasion defects, the surveillance of preeclampsia should be performed in patients with PMD.
AFE is a clinical diagnosis based on the triad of a sudden blood pressure drop with desaturation, profound coagulopathy, and correlation with the timing of delivery after excluding other potential causes. In our case, severe pulmonary embolism causing desaturation and right ventricular strain, leading to cardiogenic shock, should be ruled out in the first place. However, such extent of pulmonary embolism would also result in severe shunting (V/Q mismatch), causing profound desaturation despite ventilation support and should not have recovered in a short period of time. Our patient experienced an episode of desaturation (SpO2 81%) under general anesthesia with mechanical ventilation. Her desaturation recovered within 5 min following the administration of norepinephrine 25 mcg in two doses followed by hydrocortisone 100 mg and oxygen support. This clinical course can be better explained by sudden pulmonary vasoconstriction triggered by the anaphylactoid reaction from the exposure to amniotic materials, rather than cardiogenic shock resulting from large pulmonary emboli. Second, as the patient had experienced frequent uterine contractions followed by vaginal bleeding, given that she had placenta previa totalis, placental abrution should be considered in this scenario. Nevertheless, we did not find the presence of retroplacental hematoma after placenta expulsion, nor were there any signs of Couvelaire uterus intraoperatively. Finally, hemorrhage-associated disseminated intravascular coagulation (DIC) should also be excluded in this case. However, patient’s hypotension and desaturation were not precipitated by tachycardia. The total blood loss was 228 g antepartum and 890 ml during the surgery. Given that the patient had also received 4 units of packed-RBC transfusion intraoperatively, this amount of blood loss was less likely to be responsible for the desaturation and profound DIC observed in our patient. After the exclusion of potential causes, AFE was strongly suspected, as our case fulfilled the diagnostic criteria proposed by the Society for Maternal-Fetal Medicine and the Amniotic Fluid Embolism Foundation, namely: 1) desaturation (peripheral SpO2 < 90%) and hypotension (SBP < 90 mmHg); 2) clinical onset within 30 min of delivery of the placenta; 3) afebrile during labor; and 4), documentation of overt DIC with a score ≥ 3 using the Modified International Society on Thrombosis and Hemostasis scoring system for overt DIC in pregnancy [13].
Most AFE risk factors are associated with conditions that increase disruption of the maternal-fetal interface, including cesarean section, instrumental vaginal delivery, placental anomalies (previa, accreta and abruption), polyhydramnios, cervical laceration and uterine rupture [14, 15]. Other risk factors are advanced maternal age, preeclampsia or eclampsia, multiple gestations, and fetal distress [14, 15]. First, our patient presented with an enlarged placenta that occupied the entire lower segment of the uterus, resulting in placenta previa totalis, leaving cesarean section as the only option for delivery. Second, as the bulky placenta was widely attached to the endometrium, an increased extent of maternal-fetal interface disruption may also occur during manual expulsion of the placenta, thereby increasing the risk of AFE. In hindsight, an “en caul” delivery could have possibly avoided the breach of the maternal-fetal interface. Furthermore, in addition to the advanced maternal age of our patient, imbalanced maternal serum angiogenic markers resulted from the chronically hypoxic placenta may also lead to preeclampsia, another known AFE risk factor [14]. Finally, whether certain antigenic substances that are more prone to trigger an anaphylactoid reaction in the maternal serum exist in the PMD placenta remains a question. Given that no specific material causing AFE has been identified in the current literature, our hypothesis cannot be verified.
To the best of our knowledge, this is the first reported case of PMD complicated with IUFD and AFE. While FGR can be monitored by color Doppler, our case echoed previous reports that IUFD may be unpreventable even under intensive surveillance in PMD cases. Finally, although AFE is considered unpredictable, it is noteworthy that PMD could result in cumulative risk factors that contribute to AFE. Whether a specific link exists between the pathophysiology of PMD and AFE requires further investigation.
Anzeige
Acknowledgements
The authors would like to thank the Department of Anesthesiology of Taichung Veterans General Hospital for the instant support and vigorous effort in helping this patient surviving AFE. The authors would also like to thank professor Poon and Editage for language editing of this manuscript.
Presentation
This manuscript has not been presented elsewhere, in part or in whole.
Declarations
Ethics approval and consent to participate
The manuscript follows the Declarations of Helsinki, and a written informed consent was obtained from the patient to participate.
Consent for publication
A written informed consent was obtained from the patient for the publication of this case report. A copy of the consent form is available for the Editor to review upon request.
Anzeige
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.
Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.
Update Gynäkologie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.